1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc.

RVPHW
Reviva Pharmaceuticals Holdings, Inc.US flagNASDAQ Capital Market
0.00
USD
+0.00
- -
343,911.00Market Cap
Reviva Pharmaceuticals Holdings, Inc.
RVPHW
(NASDAQ Capital Market)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-4
-9
-28
-39
-30
-20
-17
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-7
7
29
9
7
- -
8
17
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-7
5
29
8
6
1
9
17
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
6
13
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
14
15
24
Cash, Cash Equivalents & STI
13
14
22
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
10
7
6
Payables & Accruals
9
6
5
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
240.13%
964.23%
Free Cash Flow
- -
56.24%
-26.68%
Net Income, GAAP
- -
67.68%
-33.6%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Sequenom Inc. (SQNM)
Ocular Therapeutix, Inc. (OCUL)
Unity Biotechnology, Inc. (UBX)
Medicenna Therapeutics Corp. (MDNA)
Altimmune, Inc. (ALT)
CytoMed Therapeutics Limited (GDTC)
Business
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is a late-stage clinical biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics addressing unmet medical needs in central nervous system, respiratory, inflammatory and cardiometabolic diseases. The company, founded in 2018 and headquartered in Cupertino, California, employs a chemical genomics-driven technology platform and proprietary chemistry to advance its pipeline, which centers on two new chemical entities discovered in-house: brilaroxazine (RP5063), a serotonin/dopamine modulator in phase 3 for schizophrenia, bipolar disorder, major depressive disorder and attention-deficit/hyperactivity disorder, with additional development for pulmonary arterial hypertension, idiopathic pulmonary fibrosis and topical psoriasis, as well as potential expansion into Parkinson's psychosis and Alzheimer's agitation; and RP1208, a triple reuptake inhibitor in preclinical stages targeting depression and obesity. Reviva operates primarily in the United States with global patent protections in key markets including Europe, China and Japan, focusing on patients with chronic neuropsychiatric and respiratory conditions. Recent developments include a $9 million public offering priced in September 2025 comprising 27 million shares and Series E/F warrants to fund brilaroxazine advancement; a planned Q4 2025 pre-NDA meeting with the FDA for schizophrenia ahead of a potential Q2 2026 NDA submission; grants of European and other international patents for brilaroxazine in pulmonary fibrosis; presentation of anti-inflammatory data from the RECOVER 12-month open-label extension trial at Neuroscience 2025; and prior 2024/2025 capital raises of $10 million in June 2025 and $18 million in December 2024 amid preparation for the RECOVER-2 phase 3 schizophrenia trial.